Federica Mannino, Giovanni Pallio, Roberta Corsaro, Letteria Minutoli, Domenica Altavilla, Giovanna Vermiglio, Alessandro Allegra, Ali H Eid, Alessandra Bitto, Francesco Squadrito, Natasha Irrera
Cannabinoid receptors, which are widely distributed in the body, have been considered as possible pharmacological targets for the management of several tumors. Cannabinoid type 2 receptors (CB2Rs) belong to the G protein-coupled receptor family and are mainly expressed in hematopoietic and immune cells, such as B-cells, T-cells, and macrophages; thus, CB2R activation might be useful for treating cancers affecting plasma cells, such as multiple myeloma (MM). Previous studies have shown that CB2R stimulation may have anti-proliferative effects; therefore, the purpose of the present study was to explore the antitumor effect of beta-caryophyllene (BCP), a CB2R agonist, in an in vitro model of MM...
November 16, 2021: Cancers